RxDoctor Payments Data

Mary Barringer

Obstetrics & Gynecology · Dearborn, MINPI 1952647083

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $14,634 of the $18,536 with a category attached, or 78.9%. GSK accounts for 93.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $12,863 and has fallen 94.8% since, to $671 in 2025. Among obstetrics & gynecology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,536in general payments, 2019–2025

Across 78 payments — averaging $237.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$17K
  • Merck$437
  • AstraZeneca$198
  • AbbVie$174
  • Caris MPI, Inc.$145
  • Pfizer$84
  • plus $170 from 3 others

What the payments were for

  • Speaking & faculty fees$14,63479%
  • Travel & lodging$1,96011%
  • Food & beverage$1,94210%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK32$17,328
Merck18$437
AstraZeneca10$198
AbbVie3$174
Caris MPI, Inc.4$145
Pfizer3$84
Clovis Oncology, Inc.4$76
Medtronic3$74
Seagen Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,536 in reported general payments places this provider in the 95th percentile of 1,474 obstetrics & gynecology providers in Michigan.

See all obstetrics & gynecology providers in Michigan

Medicare billing

Part B allowed, 2024
$10,054
Medicare patients
98
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate26$482,431
LynparzaOlaparib12$116,780
Gabapentin105$1,000
Pregabalin75$867
Prochlorperazine Maleate72$836
Omeprazole55$801
Estradiol16$557
Ondansetron Hcl86$518
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen56$475
Lidocaine-PrilocaineLidocaine/Prilocaine43$475
Clobetasol Propionate12$363
Olanzapine45$362
Nystatin19$353
Ibuprofen48$249
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKZejula$17,328$482,43126 claims
AstraZenecaLynparza$198$116,78012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,474 obstetrics & gynecology providers in Michigan.

Other obstetrics & gynecology in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →